{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:12:49Z","timestamp":1790035969758,"version":"4.0.1"},"reference-count":258,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004413","name":"Turkish Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004413","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.cca.2020.03.008","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T11:22:58Z","timestamp":1583493778000},"page":"92-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["The endothelin system as target for therapeutic interventions in cardiovascular and renal disease"],"prefix":"10.1016","volume":"506","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-7385","authenticated-orcid":false,"given":"Eray","family":"Eroglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Kocyigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2020.03.008_b0005","doi-asserted-by":"crossref","DOI":"10.7150\/ijbs.7502","article-title":"The vascular endothelium and human diseases","author":"Rajendran","year":"2013","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.cca.2020.03.008_b0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41581-018-0098-z","article-title":"Endothelium structure and function in kidney health and disease","volume":"15","author":"Jourde-Chiche","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/HJH.0000000000001599","volume":"36","author":"Rossi","year":"2018","journal-title":"J. Hypertens."},{"key":"10.1016\/j.cca.2020.03.008_b0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41569-019-0176-3","article-title":"Endothelins in cardiovascular biology and therapeutics","volume":"16","author":"Dhaun","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0025","article-title":"Most exposed: the endothelium in chronic kidney disease","author":"Vila Cuenca","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2020.03.008_b0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/kisup.2011.6","article-title":"The dysfunctional endothelium in CKD and in cardiovascular disease: Mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda","volume":"1","author":"Fliser","year":"2011","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.cca.2020.03.008_b0035","doi-asserted-by":"crossref","DOI":"10.1038\/263663a0","article-title":"An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation","author":"Moncada","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.cca.2020.03.008_b0040","doi-asserted-by":"crossref","DOI":"10.1038\/288373a0","article-title":"The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine","author":"Furchgott","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.cca.2020.03.008_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/327524a0","article-title":"Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor","author":"Palmer","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.cca.2020.03.008_b0050","doi-asserted-by":"crossref","first-page":"C550","DOI":"10.1152\/ajpcell.1985.248.5.C550","article-title":"Characterization of a coronary vasoconstrictor produced by cultured endothelial cells","volume":"248","author":"Hickey","year":"1985","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0055","doi-asserted-by":"crossref","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.cca.2020.03.008_b0060","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.86.8.2863","article-title":"The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes","author":"Inoue","year":"1989","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cca.2020.03.008_b0065","doi-asserted-by":"crossref","first-page":"14954","DOI":"10.1016\/S0021-9258(18)63795-0","article-title":"The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression","volume":"264","author":"Inoue","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2020.03.008_b0070","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/00004872-199816080-00001","article-title":"Endothelin as a regulator of cardiovascular function in health and disease","volume":"16","author":"Haynes","year":"1998","journal-title":"J. Hypertens."},{"key":"10.1016\/j.cca.2020.03.008_b0075","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.pharmtox.41.1.851","article-title":"Endothelin system: the double-edged sword in health and disease","volume":"41","author":"Kedzierski","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.cca.2020.03.008_b0080","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM199508103330607","article-title":"Endothelins","volume":"333","author":"Levin","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2020.03.008_b0085","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI117470","article-title":"Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1","author":"Haynes","year":"1994","journal-title":"J. Clin. Invest. 94"},{"key":"10.1016\/j.cca.2020.03.008_b0090","doi-asserted-by":"crossref","DOI":"10.1038\/348730a0","article-title":"Cloning and expression of a cDNA encoding an endothelin receptor","author":"Arai","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.cca.2020.03.008_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/0006-291X(91)91601-8","article-title":"Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes","author":"Williams","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2020.03.008_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2013.06.032","article-title":"Updated treatment algorithm of pulmonary arterial hypertension","author":"Gali\u00e8","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0105","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/HYPERTENSIONAHA.119.12105","article-title":"Endothelin: 30 years from discovery to therapy","volume":"74","author":"Barton","year":"2019","journal-title":"Hypertens (Dallas Tex. 1979)"},{"key":"10.1016\/j.cca.2020.03.008_b0110","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.tips.2007.10.002","article-title":"Selective and mixed endothelin receptor antagonism in cardiovascular disease","volume":"28","author":"Dhaun","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.cca.2020.03.008_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/0092-8674(94)90425-1","article-title":"ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1","author":"Xu","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.cca.2020.03.008_b0120","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejim.2007.04.002","article-title":"Endothelins in health and disease","volume":"18","author":"Shah","year":"2007","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.cca.2020.03.008_b0125","doi-asserted-by":"crossref","DOI":"10.1006\/bbrc.1994.1395","article-title":"Clearance of circulating endothelin-1 by etb receptors in rats","author":"Fukuroda","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2020.03.008_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/0006-291X(90)90649-8","article-title":"Tissue distribution and half-life of 125I-endothelin in the rat: importance of pulmonary clearance","author":"Sirvi\u00f6","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2020.03.008_b0135","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.81.4.1415","article-title":"Effect of endothelin-1 in man","author":"Vierhapper","year":"1990","journal-title":"Circulation"},{"issue":"6303","key":"10.1016\/j.cca.2020.03.008_b0140","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/348730a0","article-title":"Cloning and expression of a cDNA encoding an endothelin receptor","volume":"348","author":"Arai","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.cca.2020.03.008_b0145","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0006-291X(05)81089-7","article-title":"Identification of high affinity endothelin-1 receptor subtypes in human tissues","volume":"180","author":"Williams","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2020.03.008_b0150","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/pr.54.2.219","article-title":"International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature","volume":"54","author":"Davenport","year":"2002","journal-title":"Pharmacol. Rev."},{"issue":"Supplement 8","key":"10.1016\/j.cca.2020.03.008_b0155","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00005344-199322008-00008","article-title":"Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle","volume":"22","author":"Davenport","year":"1993","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b0160","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.85.24.9797","article-title":"Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor","author":"de Nucci","year":"1988","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cca.2020.03.008_b0165","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.97.8.752","article-title":"Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade","author":"Verhaar","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/0165-6147(94)90120-1","article-title":"Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans?","author":"Davenport","year":"1994","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.cca.2020.03.008_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/0022-1759(89)90012-4","article-title":"A sensitive sandwich-enzyme immunoassay for human endothelin","author":"Suzuki","year":"1989","journal-title":"J. Immunol. Methods."},{"key":"10.1016\/j.cca.2020.03.008_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/0006-291X(91)91810-Y","article-title":"Endothelin-1 and endothelin-3 play different roles in acute and chronic alterations of blood pressure in patients with chronic hemodialysis","author":"Miyauchi","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2020.03.008_b0185","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1476-5381.2011.01786.x","article-title":"Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer","volume":"168","author":"Ling","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF02576362","article-title":"Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine","volume":"194","author":"Rolinski","year":"1994","journal-title":"Res. Exp. Med. (Berl)"},{"key":"10.1016\/j.cca.2020.03.008_b0195","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/01.STR.22.3.378","article-title":"Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells","volume":"22","author":"Yoshimoto","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.cca.2020.03.008_b0200","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-118-6-199303150-00006","article-title":"Influence of sex hormones on plasma endothelin levels","author":"Polderman","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cca.2020.03.008_b0205","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0002-9149(96)00344-X","article-title":"Racial and gender differences in endothelin-1","volume":"78","author":"Evans","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0210","doi-asserted-by":"crossref","DOI":"10.1161\/01.HYP.28.4.652","article-title":"Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension","author":"Ergul","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2020.03.008_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/S0895-7061(02)03060-1","article-title":"Elevated plasma endothelin-1 levels in diabetes mellitus","author":"Schneider","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.cca.2020.03.008_b0220","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00005344-199910000-00016","article-title":"Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men","volume":"34","author":"Seljeflot","year":"1999","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b0225","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0002-8703(96)90363-4","article-title":"Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure","volume":"131","author":"Krum","year":"1996","journal-title":"Am. Heart J."},{"key":"10.1016\/j.cca.2020.03.008_b0230","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1365-2362.1999.00407.x","article-title":"Beta-blockers reduce the release and synthesis of endothelin-1 in human endothelial cells","volume":"29","author":"Garlichs","year":"1999","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.cca.2020.03.008_b0235","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/01.CIR.102.10.1132","article-title":"Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy","volume":"102","author":"Stangl","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0240","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1172\/JCI1500","article-title":"Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells","volume":"101","author":"Hern\u00e1ndez-Perera","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2020.03.008_b0245","doi-asserted-by":"crossref","DOI":"10.1159\/000046648","article-title":"Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia","author":"Nakamura","year":"2001","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b0250","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jss.2003.10.011","article-title":"Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells","volume":"119","author":"Verma","year":"2004","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.cca.2020.03.008_b0255","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.94.9.2131","article-title":"Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ET(A) receptor blockade in chronic heart failure patients treated with ACE inhibitors","author":"Love","year":"1996","journal-title":"Circulation."},{"key":"10.1016\/j.cca.2020.03.008_b0260","doi-asserted-by":"crossref","DOI":"10.1038\/sj.jhh.1001403","article-title":"Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors","author":"Hlubock\u00e1","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.cca.2020.03.008_b0265","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.cca.2020.03.008_b0270","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2362.1992.tb01463.x","article-title":"Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation","volume":"22","author":"Wagner","year":"1992","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.cca.2020.03.008_b0275","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ki.1994.284","article-title":"Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology","volume":"46","author":"Rabelink","year":"1994","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2020.03.008_b0280","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1440-1681.1989.tb01551.x","article-title":"Endothelin is blood vessel selective: studies on a variety of human and dog vessels in vitro and on regional blood flow in the conscious rabbit","volume":"16","author":"Cocks","year":"1989","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0285","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.92.3.357","article-title":"Endothelin ET A and ET B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo","volume":"92","author":"Haynes","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0290","doi-asserted-by":"crossref","first-page":"H2033","DOI":"10.1152\/ajpheart.1989.257.6.H2033","article-title":"Endothelin is a potent long-lasting vasoconstrictor in men","volume":"257","author":"Clarke","year":"2017","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0295","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2125.1991.tb05573.x","article-title":"The effect of intra-arterial endothelin on resting blood flow and sympathetically mediated vasoconstriction in the forearm of man","volume":"31","author":"Cockcroft","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b0300","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1172\/JCI114601","article-title":"Endothelin-1 mRNA is widely expressed in porcine and human tissues","volume":"85","author":"Nunez","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2020.03.008_b0305","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1042\/cs0900037","article-title":"Expression of endothelin peptides and Mrna in the human heart","volume":"90","author":"Plumpton","year":"1996","journal-title":"Clin. Sci."},{"key":"10.1016\/j.cca.2020.03.008_b0310","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/01.RES.68.1.269","article-title":"Endothelin and increased contractility in adult rat ventricular myocytes. Role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na+-H+ exchanger","volume":"68","author":"Kramer","year":"1991","journal-title":"Circ. Res."},{"key":"10.1016\/j.cca.2020.03.008_b0315","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.101.2.142","article-title":"Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist","volume":"101","author":"MacCarthy","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0320","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0022-3565(25)22781-1","article-title":"Effects of endothelin on regional blood flows in squirrel monkeys","volume":"250","author":"Clozel","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cca.2020.03.008_b0325","first-page":"H339","article-title":"Lethal ischemia due to intracoronary endothelin in pigs","volume":"257","author":"Ezra","year":"1989","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0330","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/01.CIR.97.8.744","article-title":"Endothelin receptors in the failing and nonfailing human heart","volume":"97","author":"P\u00f6nicke","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0335","series-title":"Endothelin in Renal Physiology and Disease","author":"Barton","year":"2011"},{"key":"10.1016\/j.cca.2020.03.008_b0340","first-page":"F217","article-title":"Renal microvascular effects of endothelin","volume":"259","author":"Edwards","year":"1990","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0345","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(88)90243-7","article-title":"Endothelin: an important factor in acute renal failure?","volume":"2","author":"Firth","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2020.03.008_b0350","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0014-2999(89)90417-2","article-title":"Effect of endothelin on renal function in rats","volume":"163","author":"L\u00f3pez-Farr\u00e9","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b0355","first-page":"F1051","article-title":"Endothelin: a potent renal and systemic vasoconstrictor peptide","volume":"256","author":"King","year":"1989","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0360","doi-asserted-by":"crossref","first-page":"C1101","DOI":"10.1152\/ajpcell.1989.257.6.C1101","article-title":"Endothelin, a peptide inhibitor of Na(+)-K(+)-ATPase in intact renaltubular epithelial cells","volume":"257","author":"Zeidel","year":"2017","journal-title":"Am. J. Physiol. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0365","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1172\/JCI114667","article-title":"Effects of endothelin on peptide-dependent cyclic adenosine monophosphate accumulation along the nephron segments of the rat","volume":"85","author":"Tomita","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2020.03.008_b0370","first-page":"F951","article-title":"Endothelin-1 inhibits AVP-stimulated osmotic water permeability in rat inner medullary collecting duct","volume":"261","author":"Oishi","year":"1991","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0375","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/00003246-199706000-00011","article-title":"Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines","volume":"25","author":"Cunningham","year":"1997","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.cca.2020.03.008_b0380","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0014-5793(88)80489-7","article-title":"Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells","volume":"238","author":"Komuro","year":"1988","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cca.2020.03.008_b0385","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1172\/JCI113880","article-title":"Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways","volume":"83","author":"Badr","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2020.03.008_b0390","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/01.RES.69.1.209","article-title":"Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes","volume":"69","author":"Ito","year":"1991","journal-title":"Circ. Res."},{"key":"10.1016\/j.cca.2020.03.008_b0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00060.2009","article-title":"Regulation of blood pressure and salt homeostasis by endothelin","volume":"91","author":"Kohan","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.cca.2020.03.008_b0400","first-page":"H1747","article-title":"Central effect of endothelin on blood pressure in conscious rats","volume":"256","author":"Ouchi","year":"1989","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0405","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/01.HYP.17.6.1192","article-title":"Central effect of endothelin on neurohormonal responses in conscious rabbits","volume":"17","author":"Matsumura","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2020.03.008_b0410","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004872-199101000-00011","article-title":"Chronic intracerebroventricular infusions of endothelin elevate arterial pressure in rats","volume":"9","author":"Nishimura","year":"1991","journal-title":"J. Hypertens."},{"key":"10.1016\/j.cca.2020.03.008_b0415","doi-asserted-by":"crossref","first-page":"S385","DOI":"10.1097\/00005344-199100177-00108","article-title":"Localization of [125I]Endothelin binding sites in the region of the carotid bifurcation and brainstem of the cat","volume":"17","author":"Spyer","year":"1991","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.cca.2020.03.008_b0420","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/01.CIR.82.1.188","article-title":"Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm?","volume":"82","author":"Yang","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0425","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.96.5.1593","article-title":"Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist","volume":"96","author":"Moreau","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0430","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1006\/bbrc.1997.7394","article-title":"Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ET(A) receptors for endothelin regulation","volume":"238","author":"Barton","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2020.03.008_b0435","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1172\/JCI114226","article-title":"Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion","volume":"84","author":"Cozza","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2020.03.008_b0440","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0024-3205(89)90200-2","article-title":"Endothelin stimulates release of atrial natriuretic peptides in vitro and in vivo","volume":"45","author":"Stasch","year":"1989","journal-title":"Life Sci."},{"issue":"4941","key":"10.1016\/j.cca.2020.03.008_b0445","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1126\/science.2405487","article-title":"Endothelin: a novel peptide in the posterior pituitary system","volume":"247","author":"Yoshizawa","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.cca.2020.03.008_b0450","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/jcem-72-3-693","article-title":"Endothelin in human brain and pituitary gland: presence of immunoreactive endothelin, endothelin messenger ribonucleic acid, and endothelin receptors","volume":"72","author":"Takahashi","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2020.03.008_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anireprosci.2017.09.008","article-title":"Current status of the role of endothelins in regulating ovarian follicular function: a review","volume":"186","author":"Ervin","year":"2017","journal-title":"Anim. Reprod. Sci."},{"key":"10.1016\/j.cca.2020.03.008_b0460","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2265.1993.tb02363.x","article-title":"Endothelins as regulators of growth and function in endocrine tissues","volume":"39","author":"Kennedy","year":"1993","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.cca.2020.03.008_b0465","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0006-291X(90)90614-S","article-title":"Plasma concentrations of endothelin-1 in spontaneously hypertensive rats and DOCA-salt hypertensive rats","volume":"167","author":"Suzuki","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2020.03.008_b0470","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/01.HYP.18.1.93","article-title":"Plasma immunoreactive endothelin-1 in experimental malignant hypertension","volume":"18","author":"Kohno","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2020.03.008_b0475","doi-asserted-by":"crossref","first-page":"S408","DOI":"10.1097\/00005344-199100177-00115","article-title":"Endothelin-1 release from mesenteric arteries of spontaneously hypertensive rats","volume":"17","author":"Miyamori","year":"1991","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b0480","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/01.HYP.21.3.294","article-title":"Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats","volume":"21","author":"Lariviere","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2020.03.008_b0485","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000159151","article-title":"Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure","volume":"33","author":"Schiffrin","year":"1996","journal-title":"J. Vasc. Res."},{"key":"10.1016\/j.cca.2020.03.008_b0490","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/01.HYP.14.4.427","article-title":"Characteristics of pressor response to endothelin in spontaneously hypertensive and Wistar-Kyoto rats","volume":"14","author":"Miyauchi","year":"1989","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2020.03.008_b0495","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/00004872-199411000-00004","article-title":"Experimental hypertension produces diverse changes in the regional vascular responses to endothelin-1 in the rabbit and the rat","volume":"12","author":"Roberts-Thomson","year":"1994","journal-title":"J. Hypertens."},{"key":"10.1016\/j.cca.2020.03.008_b0500","doi-asserted-by":"crossref","DOI":"10.1093\/ajh\/6.8.667","article-title":"Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype a antagonist) on blood pressure in hypertensive rats","volume":"6","author":"McMahon","year":"1993","journal-title":"Am. J. Hypertens."},{"issue":"5","key":"10.1016\/j.cca.2020.03.008_b0505","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004872-199405000-00009","article-title":"BQ-123, a selective endothelin subtype A-receptor antagonist, lowers blood pressure in different rat models of hypertension","volume":"12","author":"Douglas","year":"1994","journal-title":"J Hypertens"},{"key":"10.1016\/j.cca.2020.03.008_b0510","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/01.CIR.96.4.1250","article-title":"Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition","volume":"96","author":"Donckier","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0515","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators","volume":"338","author":"Krum","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2020.03.008_b0520","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/08037051.2016.1208730","article-title":"Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis","volume":"26","author":"Yuan","year":"2017","journal-title":"Blood Press."},{"key":"10.1016\/j.cca.2020.03.008_b0525","unstructured":"Clinical Study to Explore the Effects of Actelion\u2019s Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02603809."},{"key":"10.1016\/j.cca.2020.03.008_b0530","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0895-7061(02)02933-3","article-title":"Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension","volume":"15","author":"Nakov","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.cca.2020.03.008_b0535","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-201X.1997.578350000.x","article-title":"Long-lasting coronary vasoconstrictor effects and myocardial uptake of endothelin-1 in humans","volume":"159","author":"Pernow","year":"1997","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.cca.2020.03.008_b0540","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1524-6175.2007.07244.x","article-title":"Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study","volume":"9","author":"Black","year":"2007","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"10.1016\/j.cca.2020.03.008_b0545","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2020.03.008_b0550","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/HYPERTENSIONAHA.110.156976","article-title":"Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial","volume":"56","author":"Bakris","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2020.03.008_b0555","doi-asserted-by":"crossref","DOI":"10.1007\/s11906-018-0828-4","article-title":"The endothelin system: a critical player in the pathophysiology of preeclampsia","volume":"20","author":"Granger","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.cca.2020.03.008_b0560","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00004872-200404000-00013","article-title":"Plasma endothelin-1 level is related to renal function and smoking status but not to blood pressure: an epidemiological study","volume":"22","author":"Hirai","year":"2004","journal-title":"J. Hypertens."},{"key":"10.1016\/j.cca.2020.03.008_b0565","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1042\/cs0930035","article-title":"Elevated plasma and urinary endothelin-I levels in human salt-sensitive hypertension","volume":"93","author":"Ferri","year":"1997","journal-title":"Clin. Sci. (Lond)"},{"key":"10.1016\/j.cca.2020.03.008_b0570","doi-asserted-by":"crossref","first-page":"213","DOI":"10.7326\/0003-4819-114-3-213","article-title":"Hypertension associated with endothelin-secreting malignant hemangioendothelioma","volume":"114","author":"Yokokawa","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cca.2020.03.008_b0575","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/00005344-200000002-00013","article-title":"Endothelin in atherosclerosis: importance of risk factors and therapeutic implications","volume":"35","author":"d\u2019Uscio","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b0580","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/01.CIR.93.11.2068","article-title":"Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo","volume":"93","author":"Kaddoura","year":"1996","journal-title":"Circulation."},{"key":"10.1016\/j.cca.2020.03.008_b0585","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1139\/y03-012","article-title":"Endothelin-1 in chronic renal failure and hypertension","volume":"81","author":"Larivi\u00e8re","year":"2003","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b0590","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2020.03.008_b0595","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.RES.70.6.1191","article-title":"Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium","volume":"70","author":"Boulanger","year":"1992","journal-title":"Circ. Res."},{"key":"10.1016\/j.cca.2020.03.008_b0600","first-page":"819","article-title":"Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol","volume":"146","author":"Kowala","year":"1995","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cca.2020.03.008_b0605","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/0021-9150(92)90158-D","article-title":"Atherosclerotic risk factors \u2014 are there ten, or is there only one?","volume":"97","author":"Roberts","year":"1992","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.cca.2020.03.008_b0610","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJM199110033251404","article-title":"Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis","volume":"325","author":"Lerman","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2020.03.008_b0615","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1161\/01.CIR.91.4.941","article-title":"Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina","volume":"91","author":"Zeiher","year":"1995","journal-title":"Circulation."},{"key":"10.1016\/j.cca.2020.03.008_b0620","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/hc3301.094742","article-title":"Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis","volume":"104","author":"Ihling","year":"2001","journal-title":"Circulation."},{"key":"10.1016\/j.cca.2020.03.008_b0625","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/01.CIR.95.1.221","article-title":"Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis","volume":"95","author":"Minamino","year":"1997","journal-title":"Circulation."},{"key":"10.1016\/j.cca.2020.03.008_b0630","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/BF00227448","article-title":"Elevated endothelin levels in patients with hyperlipoproteinemia","volume":"72","author":"Haak","year":"1994","journal-title":"Clin. Investig."},{"key":"10.1016\/j.cca.2020.03.008_b0635","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0735-1097(00)00910-4","article-title":"Increased activity of endogenous endothelin in patients with hypercholesterolemia","volume":"36","author":"Cardillo","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0640","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/01.CIR.92.9.2426","article-title":"Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans","volume":"92","author":"Lerman","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0645","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0026-2862(92)90017-J","article-title":"Vasoconstrictor effects of endothelin-1 on myocardium microcirculation studied by the Langendorff perfusion method: differential sensitivities among microvessels","volume":"43","author":"Homma","year":"1992","journal-title":"Microvasc. Res."},{"key":"10.1016\/j.cca.2020.03.008_b0650","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0006-291X(89)80145-7","article-title":"Endothelin-induced CA-independent contraction of the porcine coronary artery","volume":"160","author":"Kodama","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2020.03.008_b0655","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.yjmcc.2015.07.014","article-title":"Endothelin-1 impairs coronary arteriolar dilation: role of p38 kinase-mediated superoxide production from NADPH oxidase","volume":"86","author":"Thengchaisri","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0660","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0735-1097(01)01692-8","article-title":"Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction","volume":"39","author":"Clozel","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0665","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1161\/01.CIR.98.21.2235","article-title":"Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease","volume":"98","author":"Wenzel","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0670","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/hrt.2008.158550","article-title":"Inhomogeneous vasomotor effects of moderate selective and non-selective endothelin-receptor blockade in stable coronary artery disease","volume":"95","author":"Wexberg","year":"2009","journal-title":"Heart."},{"key":"10.1016\/j.cca.2020.03.008_b0675","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/CIRCULATIONAHA.110.967406","article-title":"Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis","volume":"122","author":"Reriani","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0680","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0735-1097(10)80214-1","article-title":"Increased plasma endothelin-1 in the early hours of acute myocardial infarction","volume":"18","author":"Stewart","year":"1991","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0685","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/01.CIR.89.4.1573","article-title":"Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction","volume":"89","author":"Omland","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0690","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.4244\/EIJV7I12A218","article-title":"Systemic endothelin receptor blockade in ST-segment elevation acute coronary syndrome protects the microvasculature: a randomised pilot study","volume":"7","author":"Adlbrecht","year":"2012","journal-title":"EuroIntervention"},{"key":"10.1016\/j.cca.2020.03.008_b0695","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0002-9149(01)01441-2","article-title":"Coronary vasoconstriction after coronary angioplasty is attenuated by endothelin A receptor antagonism","volume":"87","author":"Kyriakides","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0700","first-page":"902","article-title":"Increased endogenous endothelin-1 in coronary circulation is associated with restenosis after coronary angioplasty","volume":"19","author":"Takase","year":"2003","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0705","doi-asserted-by":"crossref","DOI":"10.1016\/0735-1097(93)90455-A","article-title":"The epidemiology of heart failure: the Framingham study","volume":"22","author":"Ho","year":"1993","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0710","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0735-1097(01)01700-4","article-title":"Confirmation of a heart failure epidemic: findings from the resource utilization among congestive heart failure (REACH) study","volume":"39","author":"McCullough","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0715","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1161\/01.CIR.0000094397.19932.78","article-title":"Endothelin receptor blockers in cardiovascular disease","volume":"108","author":"Rich","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0720","doi-asserted-by":"crossref","first-page":"H1141","DOI":"10.1152\/ajpheart.00239.2001","article-title":"Increased endothelin-1 production in patients with chronic heart failure","volume":"286","author":"Parker","year":"2004","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0725","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/01.CIR.85.4.1374","article-title":"Plasma endothelin in chronic heart failure","volume":"85","author":"McMurray","year":"1992","journal-title":"Circulation."},{"key":"10.1016\/j.cca.2020.03.008_b0730","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/oxfordjournals.eurheartj.a015228","article-title":"Prognostic value of plasma endothelin-1 in patients with chronic heart failure","volume":"18","author":"Pousset","year":"1997","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cca.2020.03.008_b0735","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1460-9592.2003.00120.x","article-title":"Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: Role of endothelin","volume":"26","author":"Aronson","year":"2003","journal-title":"PACE - Pacing Clin. Electrophysiol."},{"key":"10.1016\/j.cca.2020.03.008_b0740","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1161\/01.CIR.99.14.1802","article-title":"Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium","volume":"99","author":"Pieske","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0745","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/01.CIR.0000105701.98663.D4","article-title":"Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice","volume":"109","author":"Yang","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0750","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1172\/JCI118544","article-title":"Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction","volume":"97","author":"Clavell","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2020.03.008_b0755","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1172\/JCI3512","article-title":"Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy","volume":"102","author":"Choukroun","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2020.03.008_b0760","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0026-0495(03)00189-6","article-title":"Attenuation of renal vasopressin V2 receptor upregulation by bosentan, an ETA\/ETB receptor antagonist","volume":"52","author":"Wong","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.cca.2020.03.008_b0765","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/01.CIR.99.4.570","article-title":"Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism","volume":"99","author":"Wada","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0770","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0735-1097(95)00520-X","article-title":"Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure","volume":"27","author":"Pacher","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0775","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/384353a0","article-title":"Inhibition of myocardial endothelin pathway improves long-term survival in heart failure","volume":"384","author":"Sakai","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.cca.2020.03.008_b0780","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1161\/01.CIR.96.6.1976","article-title":"Role of endogenous endothelin in chronic heart failure: effect of long- term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling","volume":"96","author":"Mulder","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0785","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0735-1097(99)00528-8","article-title":"Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure","volume":"35","author":"Mishima","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0790","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","article-title":"Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure","volume":"346","author":"Kiowski","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2020.03.008_b0795","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","article-title":"Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure","volume":"98","author":"S\u00fctsch","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0800","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0735-1097(03)00556-4","article-title":"Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure","volume":"42","author":"Torre-Amione","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0805","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1161\/01.CIR.101.25.2922","article-title":"Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure","volume":"101","author":"Givertz","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0810","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","article-title":"Hemodynamic and neurohumoral effects of selective endothelin A (ETA) receptor blockade in chronic heart failure: the heart failure ETA receptor blockade trial (HEAT)","volume":"106","author":"L\u00fcscher","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0815","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1053-2498(03)00062-7","article-title":"Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure","volume":"23","author":"Bergler-Klein","year":"2004","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.cca.2020.03.008_b0820","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.cca.2020.03.008_b0825","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0735-1097(03)00194-3","article-title":"Randomized Intravenous TeZosentan Study-4 Investigators, Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4)","volume":"41","author":"O\u2019Connor","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0830","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","article-title":"ENABLE investigators and committees, long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials","volume":"5","author":"Packer","year":"2017","journal-title":"JACC. Heart Fail."},{"issue":"1","key":"10.1016\/j.cca.2020.03.008_b0835","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/hrt.2006.089250","article-title":"Clinical Trials of Endothelin Antagonists in Heart Failure: Publication Is Good for the Public Health","volume":"93","author":"Kelland","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.cca.2020.03.008_b0840","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(04)16723-8","article-title":"Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Anand","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2020.03.008_b0845","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jchf.2013.12.002","article-title":"Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction","volume":"2","author":"Zile","year":"2014","journal-title":"JACC Hear. Fail."},{"key":"10.1016\/j.cca.2020.03.008_b0850","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.amjcard.2004.03.074","article-title":"Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure","volume":"94","author":"Dickstein","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0855","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1527-3466.2005.tb00175.x","article-title":"CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme","volume":"23","author":"Battistini","year":"2005","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.cca.2020.03.008_b0860","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/01.CIR.94.7.1578","article-title":"Human pulmonary circulation is an important site for both clearance and production of endothelin-1","volume":"94","author":"Dupuis","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0865","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pharmthera.2005.08.012","article-title":"Endothelin receptor antagonists","volume":"110","author":"Motte","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cca.2020.03.008_b0870","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.1995.269.5.L668","article-title":"Effects of separate and combined ET(A) and ET(B) blockade on ET-1-induced constriction in perfused rat lungs","volume":"269","author":"Sato","year":"1995","journal-title":"Am. J. Physiol. - Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0875","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.2001.280.5.L1040","article-title":"Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction","volume":"280","author":"Ivy","year":"2001","journal-title":"Am. J. Physiol. - Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0880","article-title":"Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats","volume":"268","author":"Eddahibi","year":"1995","journal-title":"Am. J. Physiol. - Hear. Circ. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b0885","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/pupt.2000.0237","article-title":"Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist","volume":"13","author":"Tilton","year":"2000","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.cca.2020.03.008_b0890","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00005344-199706000-00003","article-title":"The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats","volume":"29","author":"Chen","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b0895","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cca.2020.03.008_b0900","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2020.03.008_b0905","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-Blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b0910","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0915","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2020.03.008_b0920","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1183\/13993003.00364-2015","article-title":"Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN","volume":"46","author":"Simonneau","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cca.2020.03.008_b0925","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension","author":"Liu","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cca.2020.03.008_b0930","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0935","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1378\/chest.07-0767","article-title":"Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival","volume":"134","author":"Benza","year":"2008","journal-title":"Chest."},{"key":"10.1016\/j.cca.2020.03.008_b0940","unstructured":"European Medicines Agency, Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury, (n.d.). https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/thelin-sitaxentan-be-withdrawn-due-cases-unpredictable-serious-liver-injury_en.pdf."},{"key":"10.1016\/j.cca.2020.03.008_b0945","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2020.03.008_b0950","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b0955","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/0006-291X(89)92258-4","article-title":"Endothelin and the production of cerebral vasospasm in dogs","volume":"159","author":"Asano","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cca.2020.03.008_b0960","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/01616412.1989.11739870","article-title":"The role of endothelin in the pathogenesis of vasospasm following subarachnoid haemorrhage","volume":"11","author":"Ide","year":"1989","journal-title":"Neurol. Res."},{"key":"10.1016\/j.cca.2020.03.008_b0965","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/jcbfm.1994.41","article-title":"Endothelin levels increase in rat focal and global ischemia","volume":"14","author":"Barone","year":"1994","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.cca.2020.03.008_b0970","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1161\/hs0901.94259","article-title":"Protective effect of endothelin type A receptor antagonist on brain edema and injury after transient middle cerebral artery occlusion in rats","volume":"32","author":"Matsuo","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.cca.2020.03.008_b0975","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3171\/jns.2005.102.6.1108","article-title":"Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: effect on endothelinB receptor-mediated relaxation","volume":"102","author":"Vatter","year":"2005","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.cca.2020.03.008_b0980","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/01616412.1995.11740323","article-title":"Therapeutic effects of endothelin receptor antagonists in stroke","volume":"17","author":"Barone","year":"1995","journal-title":"Neurol. Res."},{"key":"10.1016\/j.cca.2020.03.008_b0985","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/01.STR.23.7.1014","article-title":"Increased plasma endothelin-1 in acute ischemic stroke","volume":"23","author":"Ziv","year":"1992","journal-title":"Stroke"},{"key":"10.1016\/j.cca.2020.03.008_b0990","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/jcbfm.1993.34","article-title":"Endothelin-1-induced reductions in cerebral blood flow: Dose dependency, time course, and neuropathological consequences","volume":"13","author":"Macrae","year":"1993","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.cca.2020.03.008_b0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.surneu.2005.04.014","article-title":"Endothelin-1 levels in plasma and cerebrospinal fluid of patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage","volume":"64","author":"Kessler","year":"2005","journal-title":"Surg. Neurol."},{"issue":"9","key":"10.1016\/j.cca.2020.03.008_b1000","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00701-007-1249-3","article-title":"Effects of the selective endothelin A (ETA) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage \u2013 preliminary results from a randomized clinical series","volume":"149","author":"Barth","year":"2007","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.cca.2020.03.008_b1005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.phrs.2010.12.008","article-title":"Endothelin receptor antagonists: potential in Alzheimer\u2019s disease","volume":"63","author":"Palmer","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cca.2020.03.008_b1010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1476-5381.1989.tb16876.x","article-title":"Endothelin induces an increase in renal vascular resistance and a fall in glomerular filtration rate in the rabbit isolated perfused kidney","volume":"98","author":"Cairns","year":"1989","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b1015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/gut.50.1.111","article-title":"Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure","volume":"50","author":"Anand","year":"2002","journal-title":"Gut."},{"key":"10.1016\/j.cca.2020.03.008_b1020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2014.03.002","article-title":"Selective ET(A) receptor blockade protects against cisplatin-induced acute renal failure in male rats","volume":"730","author":"Helmy","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b1025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0022-2828(90)90115-I","article-title":"Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells","volume":"22","author":"Kawaguchi","year":"1990","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.cca.2020.03.008_b1030","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/01.HYP.0000149249.09147.b4","article-title":"Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition","volume":"44","author":"Ortmann","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2020.03.008_b1035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ckj\/sfs001","article-title":"Endothelin and the podocyte","volume":"5","author":"Barton","year":"2012","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.cca.2020.03.008_b1040","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ki.1993.263","article-title":"A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression","volume":"44","author":"Benigni","year":"1993","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2020.03.008_b1045","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1161\/HYPERTENSIONAHA.113.00595","article-title":"Endothelin, kidney disease, and hypertension","volume":"61","author":"Speed","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2020.03.008_b1050","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2337\/diabetes.47.3.450","article-title":"Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes","volume":"47","author":"Benigni","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.cca.2020.03.008_b1055","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1681\/ASN.2006030208","article-title":"Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism","volume":"18","author":"Sasser","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1060","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/01.HYP.31.1.397","article-title":"Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats","volume":"31","author":"Kassab","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2020.03.008_b1065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.vph.2008.01.009","article-title":"Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats","volume":"48","author":"Vernerov\u00e1","year":"2008","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.cca.2020.03.008_b1070","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/HJH.0000000000001600","article-title":"Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II","volume":"36","author":"Rossi","year":"2018","journal-title":"J. Hypertens."},{"key":"10.1016\/j.cca.2020.03.008_b1075","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2020.03.008_b1080","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000187212","article-title":"Influence of cardiovascular damage and residual renal function on plasma endothelin in chronic renal failure","volume":"63","author":"Mallamaci","year":"1993","journal-title":"Nephron"},{"key":"10.1016\/j.cca.2020.03.008_b1085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.diabres.2007.12.024","article-title":"Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus","volume":"80","author":"Zanatta","year":"2008","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.cca.2020.03.008_b1090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.semnephrol.2006.07.006","article-title":"Endothelin role in kidney acidification","volume":"26","author":"Wesson","year":"2006","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1095","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2009.519","article-title":"Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR","volume":"77","author":"Phisitkul","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2020.03.008_b1100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ki.2010.129","article-title":"Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy","volume":"78","author":"Mahajan","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2020.03.008_b1105","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00309.2012","article-title":"Role of endothelin-1 in renal regulation of acid-base equilibrium in acidotic humans","volume":"303","author":"Pallini","year":"2012","journal-title":"Am. J. Physiol. - Ren. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b1110","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/01.CIR.0000118499.69469.51","article-title":"Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade","volume":"109","author":"Goddard","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2020.03.008_b1115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.109.132670","article-title":"Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease","volume":"54","author":"Dhaun","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2020.03.008_b1120","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/ndt\/gfm364","article-title":"Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease","volume":"22","author":"Dhaun","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2020.03.008_b1125","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1135","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/HYPERTENSIONAHA.110.167486","article-title":"Selective endothelin-a receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease","volume":"57","author":"Dhaun","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2020.03.008_b1140","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1145","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1150","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"SONAR Committees and Investigators, Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2020.03.008_b1155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(13)70029-9","article-title":"Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial","volume":"1","author":"Parvanova","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cca.2020.03.008_b1160","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS","volume":"29","author":"Trachtman","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.cca.2020.03.008_b1170","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1172\/JCI119297","article-title":"Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension","volume":"99","author":"Hocher","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2020.03.008_b1175","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/prca.200780140","article-title":"Characterization of the renal cyst fluid proteome in autosomal dominant polycystic kidney disease (ADPKD) patients","volume":"2","author":"Lai","year":"2008","journal-title":"Proteomics - Clin. Appl."},{"key":"10.1016\/j.cca.2020.03.008_b1180","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1159\/000068518","article-title":"Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease","volume":"93","author":"Ong","year":"2004","journal-title":"Nephron Exp. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1185","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1681\/ASN.V971169","article-title":"Renal endothelin system in polycystic kidney disease","volume":"9","author":"Hocher","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1190","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1681\/ASN.V441064","article-title":"Increased endothelin and endothelin receptor mRNA expression in polycystic kidneys of cpk mice","volume":"4","author":"Nakamura","year":"1993","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1195","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1681\/ASN.2006090994","article-title":"Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease","volume":"18","author":"Chang","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1200","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000328701","article-title":"Endothelin in polycystic kidney disease","volume":"172","author":"Chang","year":"2011","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1205","doi-asserted-by":"crossref","DOI":"10.1007\/s40620-018-0514-2","article-title":"The association of endothelin-1 levels with renal survival in polycystic kidney disease patients","volume":"32","author":"Kocyigit","year":"2019","journal-title":"J. Nephrol."},{"key":"10.1016\/j.cca.2020.03.008_b1210","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1097\/00003246-200006000-00028","article-title":"Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines","volume":"28","author":"Tschaikowsky","year":"2000","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.cca.2020.03.008_b1215","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF01728331","article-title":"Endothelin production in sepsis and the adult respiratory distress syndrome","volume":"22","author":"Sanai","year":"1996","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.cca.2020.03.008_b1220","doi-asserted-by":"crossref","first-page":"147616","DOI":"10.1155\/2015\/147616","article-title":"Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: relevance to the pathogenesis of systemic sclerosis","volume":"2015","author":"Elisa","year":"2015","journal-title":"J Immunol. Res."},{"issue":"10","key":"10.1016\/j.cca.2020.03.008_b1225","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00296-017-3797-z","article-title":"Endothelin-1, \u03b1-Klotho, 25(OH) Vit D levels and severity of disease in scleroderma patients","volume":"37","author":"Hajialilo","year":"2017","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.cca.2020.03.008_b1230","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/liv.12791","article-title":"Hepatopulmonary syndrome and portopulmonary hypertension: Recent knowledge in pathogenesis and overview of clinical assessment","volume":"35","author":"Raevens","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.cca.2020.03.008_b1235","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00408-018-0103-0","article-title":"Transient blockade of endothelin-1 mitigates amiodarone-induced pulmonary fibrosis","volume":"196","author":"Liu","year":"2018","journal-title":"Lung."},{"key":"10.1016\/j.cca.2020.03.008_b1240","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.33549\/physiolres.933812","article-title":"Endothelial-derived endothelin-1 promotes pulmonary vascular remodeling in bleomycin-induced pulmonary fibrosis","volume":"67","author":"Hartopo","year":"2018","journal-title":"Physiol. Res."},{"key":"10.1016\/j.cca.2020.03.008_b1245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0024-3205(98)00614-6","article-title":"Minireview: endothelins and asthma","volume":"65","author":"Goldie","year":"1999","journal-title":"Life Sci."},{"key":"10.1016\/j.cca.2020.03.008_b1250","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0140-6736(92)90077-G","article-title":"High endothelin-1 immunoreactivity in Crohn\u2019s disease and ulcerative colitis","volume":"339","author":"Murch","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2020.03.008_b1255","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00001574-199909000-00004","article-title":"Acute pancreatitis","volume":"15","author":"Hotz","year":"1999","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.cca.2020.03.008_b1260","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.3748\/wjg.v18.i32.4257","article-title":"Gene expression profiling and endothelin in acute experimental pancreatitis","volume":"18","author":"Oz","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.cca.2020.03.008_b1265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/354645","article-title":"Endothelin-1 role in human eye: a review","volume":"2010","author":"Salvatore","year":"2010","journal-title":"J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.cca.2020.03.008_b1270","first-page":"183","article-title":"Role of endothelin in the human craniofacial morphogenesis","volume":"18","author":"Barni","year":"1998","journal-title":"J. Craniofac. Genet. Dev. Biol."},{"key":"10.1016\/j.cca.2020.03.008_b1275","doi-asserted-by":"crossref","first-page":"R469","DOI":"10.1152\/ajpregu.00532.2015","article-title":"Endothelin therapeutics in cancer: Where are we?","volume":"310","author":"Rosan\u00f2","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.cca.2020.03.008_b1280","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.critrevonc.2013.08.011","article-title":"A review of the profile of endothelin axis in cancer and its management","volume":"89","author":"Irani","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cca.2020.03.008_b1285","first-page":"3907","article-title":"Predictive value of P-selectin and endothelin-1 for vascular restenosis after interventional procedures for peripheral artery disease","volume":"17","author":"Chen","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.cca.2020.03.008_b1290","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1161\/01.CIR.93.5.866","article-title":"Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents","volume":"93","author":"Noll","year":"1996","journal-title":"Circulation."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898120301108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898120301108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:53:20Z","timestamp":1757861600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898120301108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":258,"alternative-id":["S0009898120301108"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2020.03.008","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The endothelin system as target for therapeutic interventions in cardiovascular and renal disease","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2020.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}